Drug Therapy for Rheumatoid Arthritis in Adults
Biologic DMARDs Included in the Comparative Effectiveness Review
The biologic disease-modifying anti-rheumatic drugs (DMARDs) that have been studied for treatment of rheumatoid arthritis and were included in the comparative effectiveness review are:
The biologic DMARDs that target tumor necrosis factor-alpha (TNF-α) include adalimumab (Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®), and infliximab (Remicade®).
Other biologic DMARDs included in the review target immune system components other than TNF-α. They are:
Abatacept (Orencia®): Its target of activity is CD28.
Anakinra (Kineret®): Its target of activity is interleukin 1.
Rituximab (Rituxan®): Its target of activity is CD20.
Tocilizumab (Actemra®, RoActemra®): Its target of activity is the interleukin-6 receptor.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a | adalimumab | etanercept | infliximab | abatacept | anakinra | rituximab | tocilizumab
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.